AMP v. Myriad : A Surgical Strike on Blockbuster Business Models-Reference-Cited by-同舟云学术

AMP v. Myriad : A Surgical Strike on Blockbuster Business Models

Published:2013-07-03 Issue:192 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Gold Richard E.¹²³,Cook-Deegan Robert¹²³,Bubela Tania¹²³

Affiliation:

1. E. Richard Gold is James McGill Professor in the Faculty of Law, McGill University, Montreal, Quebec H3A 1W9, Canada.

2. Robert Cook-Deegan is Research Professor in the Institute for Genome Sciences & Policy and the Sanford School of Public Policy, Duke University, Durham, NC 27708–0141, USA.

3. Tania Bubela is Associate Professor in the School of Public Health, University of Alberta, Edmonton, Alberta, T6G 1C9, Canada.

Abstract

The U.S. Supreme Court’s decision in the Myriad Genetics case will promote translation of genetics-based diagnostics while preserving patent protection for other biomedical products.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference9 articles.

1. SCOTUS blog;www.scotusblog.com/case-files/cases/association-for-molecular-pathology-v-myriad-genetics-inc/.

2. Not quite a myriad of gene patents

3. Myriad Genetics: In the eye of the policy storm

4. DNA patents and diagnostics: not a pretty picture

5. Department of Health & Human Services Gene patents and licensing practices and their impact on patient access to genetic tests: Report of the Secretary’s advisory committee on Genetics Health and Society (2010);http://oba.od.nih.gov/oba/sacghs/reports/sacghs_patents_report_2010.pdf.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer;JAMA Network Open;2024-09-03

2. The Myriad Decision at 10;Annual Review of Genomics and Human Genetics;2024-08-27

3. Intellectual Property Policy at The Neuro, an Open Science Institute;Qeios;2020-07-28

4. Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?;Nature Biotechnology;2018-12

5. Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges;Journal of Law and the Biosciences;2017-11-01